Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

IL-33 Expression in Chronic Rhinosinusitis with Nasal Polyps and Its Relationship with Clinical Severity

Song W.a · Wang C.a · Zhou J.a · Pan S.b · Lin S.a

Author affiliations

Departments of aOtolaryngology and bPathology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Related Articles for ""

ORL 2017;79:323-330

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 30, 2017
Accepted: October 17, 2017
Published online: November 30, 2017
Issue release date: Published online first (Issue-in-Progress)

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 1

ISSN: 0301-1569 (Print)
eISSN: 1423-0275 (Online)

For additional information: https://www.karger.com/ORL

Abstract

Background: Chronic rhinosinusitis (CRS) is a heterogeneous disease characterized by epithelial inflammation and tissue eosinophilic infiltration. Interleukin-33 (IL-33) is a key inflammatory cytokine that mediates eosinophilic infiltration. Objective: The aim of our study was to investigate the expression and role of IL-33 in eosinophilic CRS with nasal polyps (ECRSwNP) and in noneosinophilic CRS with nasal polyps (nECRSwNP), and to analyze their correlation with clinical severity. Methods: The study enrolled 25 patients with ECRSwNP, 27 patients with nECRSwNP, and 12 control subjects, based on immunohistochemical staining. Protein and mRNA expressions of IL-33 in sinus mucosal samples were determined by immunohistochemistry and real-time polymerase chain reaction. Sino-Nasal Outcome Test-20 (SNOT-20) score, visual analog scale (VAS) score, endoscopy score, and computed tomography (CT) score were assessed preoperatively. Results: IL-33 expression levels in the CRSwNP group were significantly higher than those in the control group (p < 0.01), especially in the ECRSwNP group (p < 0.05). There were no significant differences between the ECRSwNP and nECRSwNP groups with respect to SNOT-20 score, VAS score, endoscopy score, or CT score. IL-33 mRNA expression showed a positive correlation with the number of eosinophils (p < 0.05) and endoscopy score (p < 0.05) but not with VAS score and CT score. Conclusion: IL-33 expression plays an important role in patients with CRSwNP. No significant differences were observed between the ECRSwNP and nECRSwNP groups with respect to SNOT-20 score, VAS score, endoscopy score, or CT score. IL-33 expression was correlated with eosinophil counts and endoscopy score.

© 2017 S. Karger AG, Basel


References

  1. Wang X, Du J, Zhao C: Bacterial biofilms are associated with inflammatory cells infiltration and the innate immunity in chronic rhinosinusitis with or without nasal polyps. Inflammation 2014;37:871-879.
  2. Wei P, Hu GH, Kang HY, et al: Role of the aryl hydrocarbon receptor in the pathogenesis of chronic rhinosinusitis with nasal polyps. Inflammation 2014;37:387-395.
  3. Shi JB, Fu QL, Zhang H, et al: Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy 2015;70:533-539.
  4. Tan BK, Lu G, Kwasny MJ, et al: Effect of symptom-based risk stratification on the costs of managing patients with chronic rhinosinusitis symptoms. Int Forum Allergy Rhinol 2013;3:933-940.
  5. Kennedy JL, Borish L: Chronic rhinosinusitis and antibiotics: the good, the bad, and the ugly. Am J Rhinol Allergy 2013;27:467-472.
  6. Schicht M, Knipping S, Hirt R, et al: Detection of surfactant proteins A, B, C, and D in human nasal mucosa and their regulation in chronic rhinosinusitis with polyps. Am J Rhinol Allergy 2013;27:24-29.
  7. Wang LF, Lee CH, Chien CY, et al: Serum 25-hydroxyvitamin D levels are lower in chronic rhinosinusitis with nasal polyposis and are correlated with disease severity in Taiwanese patients. Am J Rhinol Allergy 2013;27:162-165.
  8. Cao PP, Li HB, Wang BF, et al: Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol 2009;124:478-484.
  9. Baba S, Kondo K, Kanaya K, et al: Expression of IL-33 and its receptor ST2 in chronic rhinosinusitis with nasal polyps. Laryngoscope 2014;124:115-122.
  10. Haenuki Y, Matsushita K, Futatsugi-Yumikura S, et al: A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol 2012;130:184-194.e11.
  11. Asaka D, Yoshikawa M, Nakayama T, et al: Elevated levels of interleukin-33 in the nasal secretions of patients with allergic rhinitis. Int Arch Allergy Immunol 2012;158(suppl 1):47-50.
  12. Rogala B, Glück J: The role of interleukin-33 in rhinitis. Curr Allergy Asthma Rep 2013;13:196-202.
  13. Reh DD, Wang Y, Murugappan Ramanathan J, et al: Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am J Rhinol Allergy 2010;24:105-109.
  14. Glück J, Rymarczyk B, Rogala B: Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity. Inflamm Res 2012;61:547-550.
  15. Fokkens W, Lund V, Mullol J: European position paper on rhinosinusitis and nasal polyps group (in Chinese). Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008;43:317-320.
    External Resources
  16. Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, et al: Guidelines for diagnosis and treatment of chronic rhinosinusitis (2012, Kunming) (in Chinese). Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2013;48:92-94.
  17. Wen W, Liu W, Zhang L, et al: Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy. J Allergy Clin Immunol 2012;129:1522-1528.e5.
  18. Ouyang Y, Fan E, Li Y, et al: Clinical characteristics and expression of thymic stromal lymphopoetin in eosinophilic and non-eosinophilic chronic rhinosinusitis. ORL 2013;75:37-45.
  19. Liew FY, Pitman NI, Mcinnes IB: Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010;10:103-110.
  20. Schmitz J, Owyang A, Oldham E, et al: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-490.
  21. Li QC, Cheng KJ, Wang F, Zhou SH: Role of atopy in chronic rhinosinusitis with nasal polyps: does an atopic condition affect the severity and recurrence of disease? J Laryngol Otol 2016;130:640-644.
  22. Hashemian F, Baghbanian N, Majd Z, et al: The effect of thyme honey nasal spray on chronic rhinosinusitis: a double-blind randomized controlled clinical trial. Eur Arch Otorhinolaryngol 2015;272:1429-1435.
  23. Tecimer SH, Kasapoglu F, Demir UL, et al: Correlation between clinical findings and eosinophil/neutrophil ratio in patients with nasal polyps. Eur Arch Otorhinolaryngol 2015;272:915-921.
  24. Du Y, Luo Y, Yang C, et al: Discussion IL-33 and its receptor ST2 associated with the pathogenesis of allergic rhinitis (in Chinese). Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2015;29:811-814.
    External Resources
  25. Liu T, Lv C, Cao Z: Expression and role of IL-33 and its receptor ST2 in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps (in Chinese). Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2015;29:1350-1353.
    External Resources
  26. Lüthi AU, Cullen SP, Mcneela EA, et al: Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009;31:84-98.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 30, 2017
Accepted: October 17, 2017
Published online: November 30, 2017
Issue release date: Published online first (Issue-in-Progress)

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 1

ISSN: 0301-1569 (Print)
eISSN: 1423-0275 (Online)

For additional information: https://www.karger.com/ORL


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.